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Abstract 
Aim: Recently, a relationship between platelets and cancer metastasis has been 
reported.  The aim of this study is to elucidate the risk factors for extra-hepatic 
metastasis (EHM), with emphasis on association with platelets in patients, with 
hepatocellular carcinoma (HCC). 
Methods: We examined risk factors for EHM in 1613 consecutive, newly diagnosed 
HCC patients by logistic regression analysis (case-control study).  We also 
examined the factors by Cox proportional hazard model in a retrospective cohort 
fashion in 803 patients who received non-curative treatment for HCC. 
Results: In the case-control study, multivariate analysis revealed that high platelet 
counts [odds ratio (OR)=4.84; 95% confidence interval (CI)=1.29－29.54; p=0.01], 
high tumor number, and the presence of macroscopic vascular invasion were 
significantly associated with EHM.  In the cohort study, EHM was diagnosed in 
71 patients during the study period (mean observation time=23.3 months).  On 
multivariate analysis, high tumor number, high des-gamma-carboxy prothrombin 
(DCP), and Child-Pugh class A were significantly correlated with EHM, and the 
patients with high platelet counts tended to develop EHM (OR=1.73; 95% CI=0.99
－3.14; p=0.055). 
Conclusions: HCC patients with high platelet counts, as well as large numbers of 
tumors, high serum DCP, and Child-Pugh class A, are at risk for EHM. 
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Introduction 
The prognosis of hepatocellular carcinoma (HCC) patients has been 
improved due to the prevalence of surveillance systems and advances in diagnostic 
and treatment modalities [14].  There are several options for the treatment of 
HCC at early-to-intermediate stages, such as surgery, radiofrequency ablation 
(RFA), transcatheter arterial chemoembolization (TACE), and hepatic arterial 
infusion chemotherapy (HAIC).  However, in cases with extra-hepatic metastasis 
(EHM), the only available evidence-based treatment is molecular targeted therapy 
(sorafenib), and the prognosis of these patients is still poor [5, 6].  Based on the 
report of the Liver Cancer Group of Japan, the 5-year survival of HCC patients 
with EHM (TNM stage IVB) is 16.5%, which is much shorter than the average 
survival of HCC patients (54.2%) [7].  Therefore, information about risk factors 
for EHM is important in order to decide the best strategies for treating HCC. 
EHM, which is known to be closely related to dedifferentiation, is rarely 
observed when the primary lesion in the liver is well differentiated HCC.  Kanda 
et al. reported on risk factors for EHM, which included vascular invasion of HCC 
and elevated tumor markers, and most of the factors were related to tumor 
characteristics [8].  However, little is known about the relationship of EHM to 
characteristics of tumor-bearing patients. 
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Recently, several studies using animal models have demonstrated a 
relationship between platelets and metastasis of cancer [911].  The results 
indicate that EHM tends to occur when platelet counts are high.  There are 
several putative explanations, and one of them is a direct involvement of platelets: 
i.e., platelets may assist implantation by forming a clot at the target organ and 
could induce immune escape by the tumor cells. 
Frequently, HCC occurs in patients with chronic liver disease and liver 
cirrhosis.  Platelet counts often decrease with the development of liver disease 
[12].  As a result, the range of platelet counts in HCC patients is wide, meaning 
that HCC is a good candidate for examining the relationship between platelets and 
metastasis in human. 
In this study, we have sought to elucidate the role of platelets in metastasis 
by (1) analyzing characteristics of EHM-positive HCC patients at the time of the 
tumor discovery (case-control study), and (2) by analyzing risk factors of 
developing EHM in patients who received non-curative treatment for HCC 
(retrospective cohort study). 
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Methods 
Patients 
Among 1721 consecutive, newly diagnosed HCC patients who were 
admitted to Okayama University Hospital between January 1991 and August 2012, 
1613 patients for whom the necessary data was available were selected for a 
case-control study of EHM-positive and EHM-negative patients. 
For a retrospective cohort study, we selected 803 EHM-negative patients 
who received non-curative treatment (637 patients treated by TACE, and 97 
patients by HAIC).  Local ablation therapies had been applied to some of the 
HCCs in 93 of the patients.  Patients who developed EHM within the first 2 
months were considered to have already had EHM at initiation of therapy and 
were excluded from the cohort (n=1).  395 patients had a past-history of curative 
treatment (182 radio-frequency ablation, 68 percutaneous ethanol injection 
therapy, 19 microwave coagulation therapy, and 126 hepatectomy). 
Informed consent for the use of their clinical information was obtained from 
all patients in this study.  The study protocol conformed to the ethical guidelines 
of the World Medical Association Declaration of Helsinki, and it was approved by 
the ethics committee of our institute. 
 
Diagnosis and follow up 
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In accordance with the American Association for the Study of Liver 
Diseases (AASLD) guidelines, HCC was diagnosed radiologically by at least two 
imaging modalities: hyperattenuation in the arterial phase and hypoattenuation in 
the portal phase on dynamic computed tomography (CT), and/or magnetic 
resonance imaging (MRI), and tumor staining on angiography.  Fine-needle 
biopsy using abdominal ultrasonography (US) was performed as necessary in 276 
patients for confirming the diagnosis.  Vascular invasion was diagnosed 
macroscopically on the basis of dynamic computed tomography/magnetic resonance 
imaging, or abdominal ultrasonography 
After the treatment, all patients were followed with periodical dynamic 
CT/MRI, abdominal US, blood test every 13 months until EHM occurred. 
The diagnosis of EHM was based on imaging results from CT, MRI, US, or 
bone scintigraphy.  These tests were performed when we observed symptoms 
compatible with EHM, such as pain or neurological impairment, or when 
HCC-specific tumor markers were elevated.  Alpha-fetoprotein (AFP), 
des-gamma-carboxy prothrombin (DCP), and lectin-reactive AFP (AFP-L3) were 
used as HCC-specific tumor markers. 
 
Statistical procedures 
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The association between EHM and 16 clinical parameters was analyzed.  
Variables included platelet counts, gender, age, viral markers (hepatitis B virus 
surface antigen and hepatitis C virus antibody), maximum tumor size, number of 
tumors, vascular invasion, serum tumor markers (AFP and DCP), Child-Pugh 
class, albumin, total bilirubin, prothrombin time, aspartate aminotransferase 
(AST), and alanine aminotransferase.  We determined the cut-off value of the 
laboratory data based on median value.  In the retrospective cohort study, we 
used the laboratory data on admission for the initial non-curative treatment 
(before the treatment).  We included a variable “the presence of splenomegaly” in 
the analysis in addition to the 16 parameters. 
Logistic regression analysis was used in the case-control study.  Variables 
that demonstrated a p-value of <0.05 in univariate analysis were entered into the 
multiple logistic regression model. 
Survival and incidence of extra-hepatic metastasis was compared using the 
Kaplan–Meier method, and the difference was evaluated by log-rank test.  Cox's 
proportional hazard model was used for estimating the risk for EHM in the 
retrospective cohort study.  All statistical analyses were performed using JMP 
version 9 software (JMP Japan, Tokyo, Japan).  All reported p-values are 2-sided, 
and p<0.05 was considered statistically significant. 
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Results 
Case-control study 
Patients 
At the initial treatment, there were 30 EHM-positive patients and 1583 
EHM-negative patients (Table 1).  The sites of EHM were as follows: lung in 14 
patients, bone in 11, lymph node in 10, adrenal gland in 3, and peritoneum in 2.  
Four patients had EHM in multiple organs.  Median survival time (MST) was 3.4 
months in EHM-positive patients and 67 months in EHM-negative. 
 
Risk factors for the presence of EHM 
Univariate logistic regression analysis revealed that high platelet counts 
(>10×104/µL), maximum tumor size (>30 mm), number of tumors (≥4), the 
presence of vascular invasion, elevated DCP (>40 mAU/ml), elevated AST (>55 
IU/L), and the presence of hepatitis C virus antibody were significant risk factors 
for EHM (Table 2).  In multivariate analysis of parameters that showed 
significant differences in univariate analysis, high platelet counts [odds ratio 
(OR)=4.84; 95% confidence interval (CI)=1.2929.54; p=0.01], multiple tumors (≥4) 
(OR=3.01; 95% CI=1.158.51; p=0.02), and the presence of vascular invasion 
(OR=6.94; 95% CI=2.1626.68; p=<.001) were the risk factors for the presence of 
EHM. 
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Retrospective cohort study 
Patients and EHM 
There were 602 males (75%) in the study, with median age of 69 (range: 
2394) years.  Positive HCV antibody was seen in 586 patients (73%), and 125 
patients (16%) were HBs antigen-positive.  Seventeen patients (2%) were 
coinfected with HCV and HBV.  The median maximum tumor size was 24 mm 
(range: 5200mm), and the median number of HCC nodules was 3.  There were 
162 patients (21%) with tumor vascular invasion.  The median platelet counts 
was 10.6×104/µL (range: 2.2×104/µL65.3×104/µL).  Preserved liver function as 
Child-Pugh class A was seen in 516 patients (67%).   
The average observation period was 23.3 months.  During observation 
period, EHM were diagnosed in 71 patients.  The sites of newly appeared EHM 
were as follows: lung in 35 patients (4.4%), bone in 25 (3.1%), lymph node in 12 
(1.5%), and adrenal grand in 12 (1.5%).  The cumulative incidence of EHM at 0.5, 
1, 2, and 5 years was 1.6%, 4.5%, 9.2%, and 22.9%, respectively.  The cumulative 
survival after the diagnosis of EHM was as follows: 59.5% at 6 months, 24.5% at 1 
year, 11.2% at 2 years, and 4.5% at 5 years. 
 
Risk factors for EHM 
12 
Among the patients who received non-curative treatment, the incidence of 
EHM at 0.5, 1, and 2 years was 2.0, 6.2, and 13.0%, respectively, in the 
>10×104-platelets group; and it was 0.6, 2.1, and 4.2%, respectively, in the 
≤10×104-platelets group.  A significant difference between these data from the two 
groups (p=0.002) was observed (Fig. 1).  No correlation was observed between the 
site of EHM and platelet counts. 
The 16 parameters at the time of the initial non-curative treatment were 
analyzed to determine the risk factors for the occurrence of EHM by using Cox’s 
proportional hazard model.  By univariate analysis, the following parameters 
were significantly associated with EHM: high platelet counts (>10×104 /µL), 
maximum tumor size (>30mm), number of tumors (≥4), the presence of vascular 
invasion, HBV infection, HCV infection, elevated DCP, and Child-Pugh class A 
(Table 3).  No significant correlation was observed between splenomegaly and 
EHM.  On multivariate analysis for the above 8 parameters exhibiting 
significance in the univariate analysis, number of tumors (≥4) [hazard ratio (HR)= 
3.38; 95% CI=1.946.16; p<0.001], elevated DCP (HR=2.67; 95% CI=1.435.25; 
p=0.001), and Child-Pugh class A (HR=2.06; 95% CI=1.074.39; p=0.02) were the 
risk factors for EHM.  There was a tendency toward development of EHM in 
patients with high platelet counts (HR=1.73; 95% CI=0.993.14; p=0.055). 
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Discussion 
In this work, we examined the relationship between EHM and clinical 
parameters, including platelet counts, in two different studies.  In the 
case-control study with newly discovered HCC patients, platelet counts in 
EHM-positive patients was higher than that in EHM-negative patients.  The 
number of tumors and presence of vascular invasion also correlated with EHM at 
the time of the first treatment.  In the subsequent retrospective cohort study 
among patients who received non-curative treatment, the risk factors for EHM 
were identified as elevated serum DCP, multiple tumor nodules, and Child-Pugh 
class A.  There was a tendency for high platelet counts to correlate with EHM, 
although this was not statistically significant. 
We observed a clear relationship between platelet counts and EHM of HCC 
in the case-control study.  However, it was unclear whether high platelet counts 
promoted EHM or was a consequence of EHM.  In cancer patients, the presence of 
infectious disease and cytokine production by cancer cells may cause an elevation 
of platelet counts.  To eliminate these uncertainties, we performed a retrospective 
cohort study, and here also we observed that high platelet counts floated as a risk 
factor for EHM.  Platelet count also correlated with the appearance of PVTT in 
our preliminary analysis, indicating the importance of platelet in various clinical 
aspects. 
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The elevation of DCP, the presence of vascular invasion, and multiple 
nodules of HCC can be considered as risk factors of EHM associated with high 
malignant potential of HCC.  The marker DCP is associated with portal vein 
invasion and tumor angiogenesis [13], and it also correlates with autologous HCC 
cell proliferation in vitro through the DCP-Met-STAT3 signaling pathway [14].  
Moreover, portal vein invasion is a major cause of intrahepatic metastasis [15].  
All of these markers are so-called tumor factors that are characteristic of HCC. 
In contrast, high platelet counts is the only risk factor for EHM other than 
tumor factors.  There are several reports that platelets contribute to tumor 
metastasis [911].  P-selectin mediates the aggregation of activated platelets and 
tumor cells [16], whereby the platelets can then defend the aggregated tumor cells 
by forming a physical barrier against attack of circulating immune-competent cells 
[17].  Surviving tumor cells arrest within the microvasculature of distant organs 
and then subsequently exit from the blood circulation and form metastatic lesions.  
There are some reports that high platelet counts correlates with poor prognosis in 
cancers of several organs, including uterus, kidney, brain, pancreas, lung, colon, 
and breast [1824].  It is well known that liver function correlates with platelet 
counts, where platelet counts declines with advancement of liver functional 
impairment [12].  Addario et al. reported that HCC patients with better hepatic 
function show an increased risk for metastases [25].  The results of these reports 
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suggested an indirect relationship between platelet counts and EHM of HCC, and 
we have confirmed that relationship in the present study.  In addition, high 
platelet counts (>10×104/µL) was significantly associated with the presence of 
portal vein tumor thrombosis (PVTT) in both the case-control study (p<0.001) and 
the retrospective cohort study (p<0.001).  High platelet counts may associated 
with the appearance of PVTT. 
 In this study, the frequency of EHM was high in patients with Child- Pugh 
A.  Similar result was reported by Addario et al. as described previously [25].  It 
is hard to verify the reason; however, we speculated it as follows.  It is well known 
that Child-Pugh class closely correlates with survival of HCC patients.  It takes a 
certain period to metastasize to other organs so that the HCC patients with 
Child-Pugh B or C might die before the emergence of EHM.  As the result, 
Child-Pugh A arose as a risk factor for EHM. 
There are few reports examining the relationship between EHM of HCC 
and clinical parameters, including platelet counts.  Kanda et al. reported that 
advanced intrahepatic lesions, presence of vascular tumor invasion, elevated 
tumor markers, and presence of viral hepatitis were risk factors for EHM [8].  
However, platelet counts was not selected as the significant risk factor of EHM.  
The reason for this discrepancy with our results is not clear; however, the 
difference of timing in the enrollment of patients might be a possible factor.  Our 
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cohort study analyzed the parameters at the first non-curative treatment; whereas, 
in most existing reports in the literature, the clinical parameters of the patients at 
the time of the first treatment have been used.  However, HCC usually recurs 
several times, and the clinical course is long.  Therefore, the clinical parameters 
at the time of the first treatment might not directly reflect the characteristics of 
the patients at the time of EHM development. 
There are some limitations in the current study.  This experimental design 
is retrospective and was carried out as a single-center study.  The number of 
patients was relatively small, and we did not observe statistically significant 
correlations between platelet counts and EHM in the cohort study, although a 
clear tendency was observed (p=0.055).  In addition, the mechanism that platelets 
contribute to EHM of HCC has not been validated in vitro. 
From this study, which was carried out in two different experimental 
settings, we conclude that high platelet counts, large numbers of tumors, elevated 
DCP, and a good Child-Pugh class are risk factors for EHM in patients with HCC.  
The results suggest that patients with high platelet counts should be followed up 
carefully as patients at great risk for EHM. 
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Figure legends 
 
Figure 1  Incidence of extra-hepatic metastasis after initial non-curative treatment.  
The incidence of extra-hepatic metastasis at 6 months, 1 year, and 5 years 
were 2.0, 6.2, and 28.4%, respectively, in high platelets group (>10×104/µL, solid line); 
and those in low platelets group (≤10×104/µL, dotted line) were 0.6, 2.1, and 16.0%, 
respectively.  A significant difference was observed between the two groups (p=0.002). 
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Table 1. Patient characteristics at first treatment (n=1613) 
Variables EHM-positive (n=30) EHM-negative (n=1583) 
Gender (male)  25 (83%) 1126 (71%) 
Age (years) 63 (34－81) 66 (23－94) 
Viral markers   
HCV 11 (37%) 1107 (70%) 
HBV 7 (23%) 216 (14%) 
HCV + HBV 1 (3%) 37 (2%) 
Maximum tumor size (mm) 80 (11－170) 23 (8－200) 
Number of tumors   
≥4 (including massive and diffuse types) 20 (67%) 256 (17%) 
Vascular invasion (present) 23 (77%) 227 (15%) 
AFP (ng/ml) 84.4 (1.2－548867) 26.3 (0.6－453265) 
DCP (mAU/ml) 3932 (7－410500) 26 (0－1323600) 
Platelet counts (×104/µl) 21.5 (6－36.5) 10.9 (1.5－242) 
Child-Pugh grade (A/B/C) 21/9/0 1028/285/38 
Alb (g/dl) 3.77 (2.5－4.7) 3.66 (1.54－5.1) 
T.Bil (mg/dl) 0.8 (0.33－4.44) 0.87 (0.16－8.33) 
PT (%) 92 (57－134) 91 (10.3－152) 
AST (IU/L) 72.5 (14－243) 54 (12－631) 
ALT (IU/L) 55.5 (11－135) 47 (4－1082) 
   
Numbers in the tables are median values (ranges) unless otherwise noted. 
Abbreviations: EHM, extra-hepatic metastasis; HCV, positive for hepatitis C virus antibody; HBV, positive 
for hepatitis B virus antigen; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; Alb, albumin; 
T.Bil total bilirubin; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
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Table 2. Risk factors of extra-hepatic metastasis at the time of the initial treatment 
Variables Univariate  Multivariate  
 Odds ratio (95% CI) p value Odds ratio (95% CI) p-value 
Platelet counts (>10×104/µl) 10.61 (3.17－65.86) <.001* 4.84 (1.29－29.54) 0.01* 
Age (>70 years) 0.49 (0.18－1.14) 0.10   
Gender (male) 2.01 (0.83－5.98) 0.12   
AFP (>10 ng/ml) 1.13 (0.51－2.75) 0.75   
DCP (>40 mAU/ml) 3.87 (1.58－11.60) 0.002* 0.65 (0.21－2.33) 0.48 
Maximum tumor size (>30 mm) 8.53 (3.52－25.40) <.001* 2.53 (0.59－13.52) 0.21 
Number of tumors (≥4) 10.02 (4.74－22.56) <.001* 3.01 (1.15－8.51) 0.02* 
Vascular invasion (present) 18.64 (8.30－47.46) <.001* 6.94 (2.16－26.68) <.001* 
HCV 0.24 (0.11－0.50) <.001* 0.44 (0.19－1.01) 0.06 
HBV 1.85 (0.76－4.06) 0.15   
Child-Pugh grade (A) 0.69 (0.32－1.62) 0.38   
Alb (>3.5 g/dl) 1.24 (0.59－2.73) 0.55   
T. Bil (>1 mg/dl) 0.82 (0.37－2.31) 0.61   
PT (90%) 1.30 (0.63－2.76) 0.47   
AST (>55 IU/L) 2.13 (1.01－4.78) 0.04* 1.56 (0.63－4.13) 0.33 
ALT (>50 IU/L) 1.36 (0.66－2.86) 0.39   
95% CI, 95% confidence interval. Other abbreviations are the same as those listed in Table 1. 
* Significant value 
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Table 3. Risk factors of extra-hepatic metastasis after non-curative treatment 
Variables Univariate  Multivariate  
 Risk ratio (95% CI) p-value Risk ratio (95% CI) p-value 
Platelet counts (>10×104/µl) 2.17 (1.31－3.72) 0.002* 1.73 (0.99－3.14) 0.055 
Age (>70 years) 0.73 (0.43－1.21) 0.23   
Gender (male) 1.69 (0.92－3.42) 0.08   
AFP (>10 ng/ml) 1.64 (0.95－3.02) 0.07   
DCP (>40 mAU/ml) 3.49 (1.96－6.69) <.001* 2.67 (1.43－5.25) 0.001* 
Maximum tumor size (>30 mm) 2.31 (1.43－3.76) <.001* 1.22 (0.66－2.22) 0.5 
Number of tumors (≥4) 3.79 (2.29－6.55) <.001* 3.38 (1.94－6.16) <.001* 
Vascular invasion (present) 2.79 (1.66－4.59) <.001* 1.27 (0.67－2.41) 0.45 
HCV 0.52 (0.32－0.85) 0.01* 0.81 (0.43－1.60) 0.54 
HBV 1.75 (1.01－2.92) 0.04*  0.34 
Child-Pugh grade (A) 2.16 (1.18－4.36) 0.01* 2.06 (1.07－4.39) 0.02* 
Alb (>3.5 g/dl) 1.68 (1.04－2.81) 0.03*   
T. Bil (>1 mg/dl) 0.53 (0.31－0.89) 0.01*   
PT (90 %) 1.37 (0.85－2.25) 0.19   
AST (>55 IU/L) 0.81 (0.49－1.31) 0.39   
ALT (>50 IU/L) 0.81 (0.48－1.32) 0.40   
Splenomegaly 0.84 (0.40－1.89) 0.66   
95% CI, 95% confidence interval. Other abbreviations are the same as those listed in Table 1.  
* Significant value 
 
27 
Figure 1.  Incidence of extra-hepatic metastasis after initial non-curative treatment. 
 
